- Posted: 09 April 2021
- Tagged: PCR News
Initial success leads to new award for Oxford researchers
In 2019 we awarded a pilot grant to Professor Bart Cornelissen and Dr Tiffany Chan at the University of Oxford to investigate if they could make a targeted radiotherapy treatment work in more men. Based on their achievements and the potential of their approach, we’ve made a further investment so they can continue their work.
Professor Bart Cornelissen and Dr Tiffany Chan, from the University of Oxford, have received an additional $566,810 award from the charity Prostate Cancer Research (PCR) to continue their innovative work to help a new type of radiotherapy, designed to hunt out cancer even after it has spread, to benefit even more men with prostate cancer. Prostate cancer is now the most commonly diagnosed cancer in the UK and their work could lead to more personalized treatment for those with prostate cancer.
Bart and Tiffany’s project is already showing promising results on the route to improving radiotherapy for men with prostate cancer. We look forward to continuing to support their project on a larger and long-term basis and hope it will mean that more people can benefit from enhanced radiotherapy, without the side effects.Dr Naomi Elster
Head of Research and Communications, PCR
There are Lu-PSMA treatments that are already given in the UK but on a private basis’ Bart explains. ‘Whether that will hit the NHS depends on approval by NICE but given the fantastically positive data out there, the upcoming results of the VISION Phase 3 clinical trials that are very positive, and given the improvement in actual survival of patients, I think there is good hope there that that will be approved.Professor Bart Cornelissen
Perhaps, what is most exciting is that, by targeting PSMA, this therapy delivers the radiotherapy directly to the sites of the cancer, wherever they are located. It is heartening to see such progress with this treatment, and I look forward to it becoming more widespread in the future.David Matheson
Prostate cancer patient